Skip to main content
Premium Trial:

Request an Annual Quote

Embleema Wins $2M FDA Contract to Help Advance Microbial Genome Database

NEW YORK — Embleema said on Thursday that it has received a $2 million contract from the US Food and Drug Administration to help advance the agency's Database for Reference Grade Microbial Sequences (FDA-ARGOS) for combating infectious diseases.

FDA-ARGOS is a publicly available collection of sequenced microbes, including biothreat organisms and common clinical pathogens, that are suitable for regulatory use and can be used to develop diagnostic tests for infectious diseases.

With the funding, Embleema and collaborators at George Washington University and Temple University will use the Metuchen, New Jersey-based company's high-performance integrated virtual environment, or HIVE, platform, a bioinformatics and regulatory analytics program for genomic and biomarker data, to enhance FDA-ARGOS.

"We are delighted to partner with GW and Temple University to help the FDA enable academic researchers, life sciences, health agencies, and regulators to rapidly and easily access critical information for developing new vaccines, therapies, and diagnostics faster against pathogens," Embleema CEO Robert Chu said in a statement.

According to Embleema, HIVE has been used by the FDA for regulatory decision making and research projects since 2013.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.